Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > NTRA Natera > Company Executives
NTRA Natera
NamePositionSalaryService DateEducationAgeGenderUpdated
Mr. Steven Leonard ChapmanDirector, Chief Executive Officer and President23.34M----43male04/13/2022
Mr. Robert SchuerenChief Operating Officer9.80M----60male04/13/2022
Mr. Jonathan SheenaDirector and Chief Technology Officer657.99K----49male04/13/2022
Mr. Michael BrophyChief Financial Officer and Principal Accounting Officer9.76M----42male04/13/2022
Mr. Daniel RabinowitzSecretary and Chief Legal Officer3.97M----53male04/13/2022
Dr. Matthew RabinowitzExecutive Chairman of the Board10.13M----49male04/13/2022
Mr. Herm RosenmanIndependent Director356.62K----74male04/13/2022
Dr. James I. HealyIndependent Director345.58K----57male04/13/2022
Mr. Roelof Frederik BothaLead Independent Director397.01K----48male04/13/2022
Mr. Todd CozzensIndependent Director316.08K----65male04/15/2022
Dr. Roy D. Baynes, M.D.,PhDIndependent Director334.12K----67male04/13/2022
Dr. Gail B. MarcusIndependent Director310.92K----65female04/13/2022
Dr. Monica Bertagnolli, M.D.Independent Director453.15K----62female04/13/2022
Dr. Rowan E. Chapman, PhDIndependent Director336.62K----51female04/13/2022
Company Overview More
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company’s algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual’s tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.
CEO: --
Market: NASDAQ
Hot List
SymbolLatest price%Chg